Literature DB >> 28226412

RAGE polymorphisms and oxidative stress levels in Hashimoto's thyroiditis.

Maria Giannakou1, Katerina Saltiki1,2, Emily Mantzou2, Eleni Loukari2, Georgios Philippou2, Konstantinos Terzidis2, Kiriaki Lili2, Charalampos Stavrianos2, Miltiades Kyprianou1, Maria Alevizaki1,2.   

Abstract

BACKGROUND: Polymorphisms of the receptor for advanced glycation end products (RAGE) gene have been studied in various autoimmune disorders, but not in Hashimoto's thyroiditis. Also, increased oxidative stress has been described in patients with Hashimoto's thyroiditis. The aim of this study was to investigate the possible role of two common RAGE polymorphisms (-429T>C, -374T>A) in Hashimoto's thyroiditis; in parallel, we studied oxidative stress levels.
MATERIALS AND METHODS: A total of 300 consecutive euthyroid women were examined and classified into three groups: Hashimoto's thyroiditis with treatment (n = 96), Hashimoto's thyroiditis without treatment (n = 109) and controls (n = 95). For a rough evaluation of oxidative stress, total lipid peroxide levels in serum were measured. The -429T>C AluI and -374T>A MfeI polymorphisms of RAGE were studied in genomic DNA.
RESULTS: Significant association of the RAGE system with Hashimoto's thyroiditis was found only with regard to the prevalence of the -429T>C, but not with -374T>A polymorphism. The levels of oxidative stress were significantly elevated in Hashimoto's thyroiditis patients under treatment. Further analysis demonstrated that an oxidative stress cut-off value of 590 μmol/L is associated with an increased risk of progression of Hashimoto's thyroiditis from euthyroidism to hypothyroidism; this risk is further increased in carriers of the RAGE -429T>C polymorphism.
CONCLUSIONS: Our findings indicate that both examined risk factors may be implicated in the occurrence of Hashimoto's thyroiditis, but this covers only a fraction of the pathophysiology of the disease.
© 2017 Stichting European Society for Clinical Investigation Journal Foundation.

Entities:  

Keywords:  Autoimmune disease; Hashimoto's thyroiditis; RAGE gene polymorphisms; oxidative stress

Mesh:

Substances:

Year:  2017        PMID: 28226412     DOI: 10.1111/eci.12739

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  5 in total

1.  Clinical prognosis and bioinformatic analysis of primary thyroid lymphoma.

Authors:  Zhimin Bai; Lingyu Li; Tao Guan; Jiangtao Wang; Jin Zhao; Liping Su
Journal:  Medicine (Baltimore)       Date:  2021-02-12       Impact factor: 1.817

2.  Oxidative Stress-Induced Sirtuin1 Downregulation Correlates to HIF-1α, GLUT-1, and VEGF-A Upregulation in Th1 Autoimmune Hashimoto's Thyroiditis.

Authors:  Michaël Hepp; Alexis Werion; Axel De Greef; Christine de Ville de Goyet; Marc de Bournonville; Catherine Behets; Benoit Lengelé; Chantal Daumerie; Michel Mourad; Marian Ludgate; Marie-Christine Many; Virginie Joris; Julie Craps
Journal:  Int J Mol Sci       Date:  2021-04-07       Impact factor: 5.923

Review 3.  Receptor for Advanced Glycation End Products (RAGE): A Pivotal Hub in Immune Diseases.

Authors:  Qing Yue; Yu Song; Zi Liu; Lin Zhang; Ling Yang; Jinlong Li
Journal:  Molecules       Date:  2022-08-02       Impact factor: 4.927

4.  Plasmatic Soluble Receptor for Advanced Glycation End Products as a New Oxidative Stress Biomarker in Patients with Prosthetic-Joint-Associated Infections?

Authors:  Luca Massaccesi; Barbara Bonomelli; Monica Gioia Marazzi; Lorenzo Drago; Massimiliano Marco Corsi Romanelli; Daniela Erba; Nadia Papini; Alessandra Barassi; Giancarlo Goi; Emanuela Galliera
Journal:  Dis Markers       Date:  2017-12-13       Impact factor: 3.434

5.  The effect of obesity and dietary habits on oxidative stress in Hashimoto’s thyroiditis

Authors:  Maria Giannakou; Katerina Saltiki; Emily Mantzou; Eleni Loukari; Georgios Philippou; Konstantinos Terzidis; Charalampos Stavrianos; Miltiades Kyprianou; Theodora Psaltopoulou; Kalliopi Karatzi; Maria Alevizaki
Journal:  Endocr Connect       Date:  2018-09-01       Impact factor: 3.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.